Windtree Therapeutics Strengthens Leadership Amid Strategic Shift

Windtree Therapeutics ( (WINT) ) just unveiled an update.

Windtree Therapeutics has appointed Leanne Kelly to its board of directors as an independent director and chair of the audit committee, aiming to resolve a compliance deficiency with Nasdaq’s requirements. Kelly’s extensive experience in finance and leadership across life science, technology, and e-Commerce sectors is expected to strengthen Windtree’s board as the company embarks on a new strategy to acquire small biotech firms with FDA-approved products, enhancing its market positioning.

More about Windtree Therapeutics

Windtree Therapeutics, Inc. is a biotechnology company focused on advancing early and late-stage innovative therapies for critical conditions and diseases. The company’s portfolio includes istaroxime, a Phase II candidate for acute heart failure, preclinical SERCA2a activators for heart failure, and preclinical precision aPKCi inhibitors for oncology applications. Windtree also operates a licensing business model with partnership out-licenses.

YTD Price Performance: -24.78%

Average Trading Volume: 2,183,853

Technical Sentiment Consensus Rating: Buy

Current Market Cap: $2.82M

See more insights into WINT stock on TipRanks’ Stock Analysis page.